Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-
alcoholic fatty liver disease (NAFLD), is the most common liver disorder worldwide, with an …

Background and aims Non-alcoholic fatty liver disease (NAFLD) is associated with a higher
risk of heart failure (HF) than those without NAFLD. However, the prognostic impact of …

Background/Aim: Non-alcoholic fatty liver disease is a major cause of liver-related morbidity
and mortality. Metformin is a widely used medication and may have additional benefits …

Over the last few years, given the increase in the incidence and prevalence of both type 2
diabetes mellitus (T2DM) and heart failure (HF), it became crucial to develop guidelines for …

Cardiovascular diseases (CVDs) represent a prominent contributor to global morbidity and
mortality rates, with projections indicating a rise in this burden due to population aging …

Heart failure with preserved ejection fraction (HFpEF) is a prevalent and complex condition
with limited effective treatments. Endothelial dysfunction is a significant component of HFpEF …

Heart failure is a leading cause of morbidity and mortality worldwide [1], and with continued
increases in the global prevalence of key disease drivers like physical inactivity and obesity …

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is
increasingly prevalent and is the most common cause of chronic liver disease in the western …

Хроническая сердечная недостаточность (ХСН) и хронические заболевания печени
(ХЗП) являются ведущими причинами, способствующими высокой заболеваемости и …